<DOC>
	<DOCNO>NCT00674921</DOCNO>
	<brief_summary>According national guideline Uganda World Health Organization guideline , HIV-infected patient receive cotrimoxazole prophylaxis indefinitely . There , however , concern regard indefinite application cotrimoxazole prophylaxis among patient immunologically stabilize HAART ( e.g . high pill burden , drug-drug interaction , toxicity poor adherence treatment fatigue ) . To date empirical evidence available regard safety optimal timing cessation cotrimoxazole prophylaxis among HAART patient successfully restore immunological competence . Research question : Does morbidity significantly differ continuation ( orthodox ) cessation ( experimental ) cotrimoxazole prophylaxis among immuno-competent patient stable HAART resource-limited set Uganda ?</brief_summary>
	<brief_title>Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients HAART Entebbe , Uganda</brief_title>
	<detailed_description>Randomized double-blind placebo control equivalence trial conduct among consent clinically healthy patient HAART 2 CD4 count 200 cells/ul least 3 month . The study enable comparison effect randomize cessation cotrimoxazole prophylaxis 2 CD4-guided threshold ( 200 Vs 350 cells/ul ) . Rationale inclusion placebo-controlled design - The double-blind placebo control approach feasible ethically justified equipoise situation allow concealment allocate intervention among investigator patient avoids accidental unblinding investigator allocate intervention trial patient . - Maintenance continue cotrimoxazole prophylaxis among patient randomize intervention easy awareness patient randomize cessation prophylaxis relative advantage reduce pill burden . - It would difficult maintain cessation cotrimoxazole prophylaxis among patient randomize set cotrimoxazole readily cheaply available drug shop , drug store pharmacy . First randomisation Patients HAART least 3 month confirm CD4 count 200 349 cells/ul randomize continue prophylaxis active cotrimoxazole cease prophylaxis active cotrimoxazole continue ingestion placebo cotrimoxazole daily . Second randomization Patients achieve confirm CD4 count 350 cells/ul HAART randomize continue prophylaxis active cotrimoxazole cease prophylaxis active cotrimoxazole continue ingestion placebo cotrimoxazole daily . Some patient participate already 1st randomization others enter trial stage first time . Rationale 4 trial arm In order ass separate effect cessation cotrimoxazole prophylaxis trial patient 2 randomization stage , continue prophylaxis compare cease prophylaxis , necessitate 2 arm stage .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Consenting HIVinfected patient age 16 year old , Resident within 40 km study clinic Regularly attend clinic Documented HAART intake least 3 month Clinically healthy stable Confirmed CD4 count 200 cells/ul . Acutely ill patient opportunistic infection Patients already enrol HAART trial ( e.g DART trial ) First trimester pregnancy enrolment Clinical immunological evidence HAART treatment failure Unable attend study clinic regularly Hypersensitivity cotrimoxazole</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Opportunistic Infections</keyword>
	<keyword>AIDS</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>